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The year 2020 introduced far-reaching changes into the
world’s daily routine after the emergence of a coronavirus
(SARS-CoV-2), which quickly spread to cause a global
pandemic, infecting almost 70 million people and claiming
more than 1.5 million lives around the globe as of early
December 2020. Huge efforts are currently being undertak-
en by science, industry and governments together to iden-
tify drugs, vaccines and transmission prevention strategies
in order to keep the spread of the virus under control and
manage health, economic and social damage.
In an effort to combat SARS-Cov-2, clinicians and scien-
tists are repurposing known drugs to accelerate compound
identification and speed up the approval process. One of
the first compounds reported to potentially have a benefi-
cial effect on viral load and patient mortality was chloro-
quine (reviewed in [1]). However, clinical trials during the
early stages of the disease spread were done rapidly and of-
ten without proper controls, leading to conflicting results.
Chloroquine, or the closely related hydroxychloroquine, is
a widely available drug with well-known pharmacokinet-
ics. It rapidly diffuses across membranes and accumulates
in the lower pH environment of lysosomes, where it be-
comes protonated and trapped. Accumulation of the com-
pound within lysosomes raises lysosomal pH and inhibits
fusion between endosomes and lysosomes, and therefore
has a major impact on lysosomal function and impedes
late stages of autophagy where autophagosomes fuse with
lysosomes [2]. The compound has been shown to be effec-
tive against a broad range of viruses in vitro, hampering
crucial steps of low pH-dependent viral replication [3, 4].
Chloroquine also inhibits terminal glycosylation of the an-
giotensin converting enzyme-2 (ACE2) receptor through
which SARS-CoV-2 enters the cell [5] (fig. 1). In vitro,
non-glycosylated ACE2 interacts less efficiently with the
spike protein of SARS-CoV2. It is therefore not entirely
clear whether chloroquine’s effect on late autophagy is
necessarily the cause of its general antiviral activity in
vitro. In the case of COVID-19, the US Food and Drug
Administration (FDA) revoked the Emergency Use Au-
thorization for hydroxychloroquine in the treatment of
COVID-19 after interim analysis of two large randomised
trials showed no mortality benefit [6–8]. A recent meta-
analysis, preprinted in medRxiv, by a team from the Uni-
versity of Basel compared data of 26 clinical trials in-
vestigating the use of hydroxychloroquine. While this
publication still lacks peer-review, the meta-analysis found
no survival benefit for patients receiving hydroxychloro-
quine [9].
Early on during the first wave of infections in April, a
group from the virology department at Berlin’s Charité
showed great potential for autophagy modulators, includ-
ing spermidine, Akt (protein kinase B) inhibitor MK-2206
and Beclin-1 stabilising niclosamide, to inhibit SARS-
CoV-2 propagation (preprint, not peer-reviewed) [10].
Many of the more promising compounds currently inves-
tigated in clinical trials are indeed autophagy modulators,
thus substantiating the need for an understanding of how
coronaviruses interact with and utilise components of the
autophagy pathway.
Autophagy is a multistep process for lysosomal degrada-
tion of cytoplasmic content such as damaged organelles,
protein aggregates or long-lived proteins, and hence en-
sures a supply of biomass in times of nutrient starvation
and stress. Although there are different subtypes of au-
tophagy depending on cargo recognition and the method
of delivery to the lysosome, we focus solely on macroau-
tophagy for the purposes of this article. Macroautophagy
(hereafter autophagy) traps cytoplasmic contents through
the formation of a thin membrane around the cargo, called
the phagophore, which furthermore expands and closes to
become the double-membraned autophagosome.
Autophagy is involved in the immune response through
clearance of intracellular pathogens (xenophagy/vi-
rophagy), as well as through processing of antigens for
major histocompatibility complex (MHC)-dependent pre-
sentation to T cells. Several viruses have been reported to
hijack the cellular autophagy machinery to provide scaf-
fold functions for replication purposes (reviewed in [11]).
Beta coronaviruses (bCov), the family to which SARS-
CoV2 belongs, have been shown to induce an autophagy-
related gene 5 (ATG5)-dependent upregulation of au-
tophagosome formation, but subsequently inhibit their
maturation [12, 13]. Electron microscopy of cells infected
with mouse hepatitis virus (MHV), a bCov family member
used to study bCovs in the laboratory, revealed that viral
replication is indeed localised within double membraned
vesicles (DMVs, fig. 1, caption 2), much like autophago-
somes [14]. However, the same authors as well as others
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found that those DMVs contain LC3-I, rather than LC3-II,
which is found on autophagosomes, and that DMVs occur
after infection even in an autophagy-deficient background
[14] (LC3 = microtubule-associated protein 1A/1B-light
chain 3B). The upregulation of LC3-I containing DMVs
after bCov infection could therefore indicate viral hijack-
ing of another pathway, endoplasmic reticulum (ER)-as-
sociated degradation (ERAD), as DMV membranes are
thought to be derived from the ER [15]. It is not entirely
clear if or how viral replication inside DMVs is connected
to autophagy, but there is evidence of an increasing number
of autophagosomes (fig. 1, caption 3) upon bCov infection
[12, 14] and, importantly, an up to 86% reduction of MHV
replication in autophagy-incompetent cells [16]. In line
with these findings, Prentice et al. showed an upregulation
of autophagy upon MHV infection by looking at degrada-
tion of long-lived proteins as an autophagic flux assay [16].
Assessment of autophagy and autophagic flux is general-
ly challenging, as it is a multistep dynamic process, which
can involve different protein complexes and does not al-
ways include lipidation of LC3B [17]. We would therefore
like to stress the importance of assessing autophagic activ-
ity by more than one method [18]. Autophagy is a complex
process requiring a multitude of proteins with substantial
redundancy; hence, if looking closely, one finds conflict-
ing results with regards to viral replication and autophagy
inhibition. It is therefore believed that, although targeting a
single isolated autophagy gene may not always disrupt the
autophagic machinery as a whole, there may very well be
unconventional functions of ATGs important for the viral
life cycle. This notion is supported by an ATG-proteome
specific small interfering RNA (siRNA) screen across cells
infected with six different viruses, where knockdown of
autophagy proteins uncovered a complex landscape of both
viral suppression and promotion, depending on the target
[19]. Interestingly, for MHV infection, knocking down
multiple redundant components of the autophagy machin-
ery almost always led to a decrease in viral replication.
For viruses, positioning themselves within a degradation-
competent vesicle and inducing autophagy has the advan-
tage of maintaining high levels of ATP needed for replica-
tion. On the other hand, upregulation of autophagy upon
bCov infection could potentially reduce virulence through
increased clearing of viral particles. Certain coronaviruses
seem to have addressed this by developing strategies to
downregulate Beclin1 and thus inhibit late-stage au-
tophagy (reviewed in [20]). Beclin1 is also important for
early membrane rearrangements during autophagosome
formation [21], but increased numbers of autophagosomes
without an increase in autolysosomes [22] upon bCov in-
fection points towards an inhibition of mostly late-stage
autophagy, as Beclin1 is crucial for fusion of autophago-
somes, and potentially DMVs, with the lysosome [22]
(fig.1 caption 4). Viral targeting of Beclin1 is also interest-
ing as Beclin1 is a key player in antiviral interferon sig-
nalling [23]. For SARS-CoV, it has been shown that the
presence of a SARS-CoV specific protease led to Beclin1
associating with the stimulator of interferon genes pathway
(STING) and resulted in a decreased interferon-β response
[13]. Whereas massive interferon signalling arguably ag-
gravates multi-organ damage in severely ill patients, an ad-
equate interferon response at an early stage of infection
may well prove beneficial. This is highlighted by most re-
cent genome-wide studies identifying certain genetic deter-
minants of severe disease that are in part connected to in-
terferon signalling [24].
There is a large body of literature on autophagy and its
role in viral replication. Although it certainly is crucial in
the life cycles of most, if not all, viruses, whether the au-
tophagy machinery is hijacked to benefit viral replication,
or whether it is promoting antiviral defence through clear-
ance of viral particles and antigen presentation seems very
Figure 1: Overview of the autophagy pathway during viral infection. 1. ACE2/TMPRSS2 mediated endocytosis. 2. Replication of virus in-
side ER-derived DMVs containing LC3-I. 3. Induction of early stages of autophagy and accumulation of autophagosomes. 4. Viral proteins
block the fusion event between autophagosomes and lysosomes, thereby blocking late stages of autophagy. 5. MHC-mediated presentation of
viral particles upon autophagic degradation. Created with BioRender.com.ACE2 = angiotensin converting enzyme-2; DMV = double mem-
braned vesicles; ER = endoplasmic reticulum; LC3 = microtubule-associated protein 1A/1B-light chain 3B; MHC = major histocompatibility
complex; TMPRSS2 = a type II transmembrane serine protease
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much to depend on the specific type of virus. In the case
of SARS-Cov-2, the literature at this point would almost
suggest a dual role of promoting viral replication through
the early stages of autophagy and blocking later stages to
prevent clearance of viral particles and/or antigen presen-
tation (fig. 1, caption 5). The evidence so far cautiously
points towards an enhanced clearing of SARS-COv-2 in-
fection through autophagy-inducing agents. However, to
date there is no direct experimental evidence to pin down
autophagy as either a pro- or antiviral process during
COVID-19 disease. Whether or not autophagy modulators
will eventually be useful in the treatment of COVID-19
might also depend on a patient’s individual autophagic sta-
tus, and stratification might therefore be of importance
when assessing the efficiency of these drugs. Further ex-
perimental investigations, as well as analysis of autophagic
activity in patient samples, will hopefully advance treat-
ment options and lead to a better understanding of how dif-
ferent stages of autophagy are involved in viral replication
and infection control.
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